The idea that glioma stem cells and non-stem bulk tumor cells are differentially sensitive to the inhibition of MDM2 may facilitate the selection of glioblastoma patients who will benefit the most from therapies targeting the interaction between MDM2 and wild-type p53. This evidence concerns the gene MDM2 and glioblastoma.